This study will provide access to investigational anti-SARS-CoV-2 human convalescent plasma for pediatric patients with underlying medical conditions (cardiovascular disease, lung disease, immunosuppression) who are either infected with SARS-CoV-2 or who have had a high-risk exposure. Study participants will be transfused once with compatible convalescent plasma obtained from an individual who has recovered from documented infection with SARS-CoV-2. Safety information and pharmacokinetic data will be collected.
Biological: anti-SARS-CoV-2 human convalescent plasma
Single transfusion. The total volume (mL) to be transfused will be based on participant weight (kg) and will be calculated as 5 mL/kg. The maximum volume to be transfused will be 500 mL.
Inclusion Criteria:
- Age ≥ 1 month and < 18 years at the time of consent.
- Determined to be at high-risk for severe SARS-CoV-2 disease based on the American
Academy of Pediatrics definition of immunocompromised children and reported high-risk
pediatric subpopulations. These include the following groups: immunocompromised,
hemodynamically significant cardiac disease (e.g. congenital heart disease), lung
disease with chronic respiratory failure, infant, i.e. child ≤1 year old.
- Confirmed SARS-CoV-2 infection OR high-risk exposure as defined:
- Confirmed infection: Child who tested positive for COVID-19 and is no more than
96 hours after onset of symptoms (and within 120 hours at the time of receipt of
study plasma).
- High-risk exposure: Susceptible child who was not previously infected or
otherwise immune to SARS-CoV-2 and exposed within 96 hours prior to enrollment
(and within 120 hours at the time of receipt of study plasma). Both criteria
below should be met:
1. A household member or daycare center (same room) exposure to a person with
confirmed SARS-CoV-2 OR with clinically compatible disease in areas with
widespread ongoing transmission
2. Negative for SARS-CoV-2 (nasopharyngeal or oropharyngeal swab)
- For females of reproductive potential (defined as having experienced menarche), not
pregnant based on testing performed at screening.
- Parent or legal guardian able and willing to provide signed parent permission.
Exclusion Criteria:
- History of severe reactions (e.g. anaphylaxis) to transfusion of blood products.
Individuals with minor reactions such as fever, itching, chills, etc. that resolve
spontaneously or respond to pre-medications, and that do not represent more
significant allergic reactions, will not be excluded.
- For females, breastfeeding, or planning to become pregnant/breastfeed during the study
period.
- Participant is unlikely to adhere to the study procedures, keep appointments, or is
planning to relocate outside the greater Los Angeles area during the study.
- Any condition that would, in the opinion of the principal investigator, place the
participant at an unacceptable risk of injury or render the participant unable to meet
the requirements of the protocol.
University of California, Los Angeles (UCLA)
Los Angeles, California, United States
Investigator: Jaime G Deville, M.D.
Contact: 310-825-9660
jdeville@mednet.ucla.edu
Jaime G Deville, M.D.
310-825-9660
jdeville@mednet.ucla.edu
Jaime G Deville, M.D., Principal Investigator
UCLA Clinical Professor of Pediatrics